Generic Name and Formulations:
Nusinersen 12mg/5mL; soln for intrathecal inj; preservative-free.
Indications for SPINRAZA:
Spinal muscular atrophy.
Adults and Children:
Consider sedation and ultrasound or other imaging techniques as guidance. Remove 5mL of cerebrospinal fluid prior to inj. Give as intrathecal bolus inj over 1–3 mins. 12mg (5mL) per dose. Initially: give 3 loading doses at 14-day intervals then give 4th loading dose 30 days after. Maintenance: give dose once every 4 months thereafter.
Do not administer in areas of infected or inflamed skin. Increased risk of bleeding complications. Perform platelet count, prothrombin time, aPTT, quantitative spot urine protein testing at baseline, prior to each dose, and as clinically needed; consider repeat testing if urine protein >0.2g/L. Pregnancy. Nursing mothers.
Lower/upper respiratory infection, constipation, teething; thrombocytopenia, coagulation abnormalities, renal toxicity.
Neurology Advisor Articles
- Cannabis: Current Evidence and Research Recommendations
- Addressing Gender Differences in Concussion Diagnosis and Treatment
- Sphenopalatine Ganglion Stimulation May Help Treat, Prevent Cluster Headache
- Relapsing-Remitting Multiple Sclerosis Halted With Immunosuppression, Stem Cell Transplant
- Maternal Antiepileptic Use and Risk for Major Congenital Malformations in Offspring
- Persistent Asthma May Increase Migraine Risk in Children
- Updated Guidelines for Treatment of Low Back Pain
- Antiretroviral Therapy May Improve Neurodevelopmental Outcomes in HIV-Infected Infants
- Head Impacts in Soccer Lead to Moderate to Severe CNS Symptoms
- The Handoff: Your Week in Neurology News - 2/16/17